Caris Life Sciences, Inc. (CAI) Stock
7 of the hedge funds AlphaScala tracks reported CAI in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Coatue Management's at $174.99M. Company insiders reported 0 open-market buys and 5 sales on SEC Form 4 in the 90 days to Nov 2, 2026.
Which hedge funds own CAI?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Coatue Management Philippe Laffont | 9.82M | $174.99M | n/a |
| Millennium Management Israel Englander | 2.20M | $39.25M | +44% |
| Duquesne Family Office Stanley Druckenmiller | 1.89M | $33.76M | n/a |
| Renaissance Technologies Jim Simons (founder) | 568K | $10.12M | +26% |
| Citadel Ken Griffin | 298K | $5.31M | +283% |
| Marshall Wace | 223K | $3.97M | NEW |
| D.E. Shaw David Shaw | 205K | $3.65M | +58% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Caris Life Sciences, Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Sep 22, 26 | Denton John Russel | See Remarks | SELL | 7.5K | $239K |
| Sep 17, 26 | Brille Brian J | See Remarks | SELL | 400.0K | $12.1M |
| Sep 4, 26 | Spetzler David Baxley | President | SELL | 119.2K | $3.0M |
| Sep 3, 26 | Spetzler David Baxley | President | SELL | 393.1K | $9.7M |
| Sep 3, 26 | Spetzler David Baxley | President | SELL | 84.9K | $2.1M |
SEC Form 4 filings as of Nov 2, 2026
See cluster-buy signals across all tickers →CAI price chart
Powered by TradingViewWhat does Caris Life Sciences, Inc. do?
Caris Life Sciences is a leading AI-driven precision medicine company that transforms healthcare through comprehensive molecular profiling and advanced machine learning. The company specializes in analyzing cancer at the molecular level by performing whole exome and whole transcriptome sequencing on patient tissue and blood samples. Its flagship offerings include MI Profile for tissue-based profiling, Caris Assure for blood-based analysis, and Caris Detect, a multi-cancer early detection blood assay leveraging ultra-deep whole genome sequencing. Caris has built one of the world's largest multimodal clinico-genomic databases, combining genomic, transcriptomic, and proteomic data with clinical outcomes from over 740,000 matched patient records. The company serves oncologists and patients by providing molecular information to guide therapy selection, support drug development, and enable early disease detection. Founded in 2008 and headquartered in Irving, Texas, Caris operates internationally with offices across major medical and research hubs, delivering precision medicine solutions that help physicians and patients make informed treatment decisions based on individual tumor biology.